Interpace Biosciences, Inc. (IDXG)
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $5.59
- As of
Kresmion compiles this page from IDXG's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
INTERPACE BIOSCIENCES, INC. (IDXG): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-15.
See the full IDXG dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IDXG on one page. Preview it with sample data, then open it live with a free account.
Preview the IDXG dossierActive signals for IDXG
- mediumEARNINGS_BEAT
Q1-2022: Beat consensus by 31.4% - EPS $-0.56 vs $-0.816 estimate
- mediumEARNINGS_MISS
Q3-2022: Missed consensus by 1213.7% - EPS $-3.35 vs $-0.255 estimate
- mediumEARNINGS_BEAT
Beat consensus by 31.4% - EPS $-0.56 vs $-0.816 estimate
- mediumEARNINGS_MISS
Q2-2022: Missed consensus by 75.3% - EPS $-0.93 vs $-0.5304 estimate
- mediumEARNINGS_MISS
Missed consensus by 1213.7% - EPS $-3.35 vs $-0.255 estimate
FREE, NO ACCOUNT
Every signal on IDXG, as it fires
New filings, 13F moves and cross asset signals on IDXG land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, IDXG
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IDXG against its peers
IDXG's operating margin of 10.5% ranks in the 97th percentile of 16 Diagnostics & Research sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | IDXG | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 38.7M USD | 69.6M USD | 47 | 17 |
| Gross margin | 62.3% | 64.2% | 46 | 11 |
| Operating margin | 10.5% | -33.1% | 97 | 16 |
| Net margin | 63.5% | -31.8% | 92 | 17 |
| Return on equity | 109.9% | -11.6% | 90 | 14 |
| 1 year | n/a | -27.6% | n/a | 14 |
Peers (21): PRPO, MBAI, MDXH, LDDD, IMDX, AWHL, QUCY, ADVB, FONR, NDRA, BNR, XWEL, BDSX, ISPC, OPK, FUNI, PSNL, NEO, NSTM, CDNA, BLLN. Left out: ANPCF (no annual filing), PMDI (period gap), BIAF (no annual filing), NOTV (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (IDXG: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IDXG on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IDXG for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.